Monte Rosa Therapeutics Inc Asset Resilience Ratio
Monte Rosa Therapeutics Inc asset resilience ratio. Monte Rosa Therapeutics Inc (GLUE) has an Asset Resilience Ratio of 76.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Monte Rosa Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Monte Rosa Therapeutics Inc (2021–2025)
Asset resilience ratio of Monte Rosa Therapeutics Inc from 2021 to 2025. This chart shows how Monte Rosa Therapeutics Inc's Asset Resilience Ratio has changed over time. Read GLUE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Monte Rosa Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Monte Rosa Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $531.00 Million | 76.28% |
| Total Liquid Assets | $531.00 Million | 76.28% |
Asset Resilience Insights
- Very High Liquidity: Monte Rosa Therapeutics Inc maintains exceptional liquid asset reserves at 76.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Monte Rosa Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Monte Rosa Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Monte Rosa Therapeutics Inc Asset Resilience Ratio by Year (2021–2025)
Monte Rosa Therapeutics Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Monte Rosa Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.10% | $247.22 Million | $448.66 Million | +21.39pp |
| 2024-12-31 | 33.71% | $147.90 Million | $438.73 Million | -0.63pp |
| 2023-12-31 | 34.34% | $104.31 Million | $303.75 Million | -26.38pp |
| 2022-12-31 | 60.72% | $207.91 Million | $342.39 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $366.33 Million | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more